Research outlook

Where salivary gland cancer treatment is heading

Salivary gland cancer · Updated Nov 14, 2026

Salivary gland cancers start in the parotid and other glands that make saliva; a few thousand Americans are diagnosed each year. There are more than 20 types, including mucoepidermoid carcinoma, adenoid cystic carcinoma and salivary duct carcinoma, which behave very differently. Surgery, often with radiation, cures many early cancers, but there has been no standard drug treatment for advanced disease. That is changing as tumors are tested for HER2, androgen receptors and other targets, with matched drugs giving high response rates.

  1. Now

    Nov 2026

    HER2-targeted drugs work wellHappened 91.7% response rate

    A HER2 antibody-drug conjugate shrank 91.7% of HER2-high tumors; trastuzumab plus docetaxel shrank 60.0%.

    91.7%: response rate in HER2-high disease.

    Hormone blockade for androgen-receptor-positive tumorsHappened 45.2% response rate

    Darolutamide plus goserelin shrank 45.2% of tumors, without chemotherapy.

    45.2%: response rate with darolutamide plus goserelin.

    Adenoid cystic carcinoma remains hard to shrinkHappened 45% progression-free at 6 months

    Regorafenib slowed growth (45% progression-free at 6 months) but shrank no tumors.

    45%: progression-free at 6 months.

  2. 6 months

    by May 2027

    Chemotherapy with radiation after surgeryPossible

    RTOG 1008 (252 people), testing whether cisplatin improves postoperative radiation for high-risk cancers, finishes December 2026.

  3. 12 months

    by Nov 2027

    A HER2 bispecific antibodyPossible

    Jazz's zanidatamab study (200 people, including salivary cancers) finishes December 2026.

    Routine tumor testingLikely 45.5% response in HER2-low

    Testing for HER2, androgen receptor, NTRK and other targets is becoming standard for advanced disease.

    45.5%: response rate in HER2-low disease.

  4. 3 years

    by late 2029

    T-DM1 vs chemotherapyPossible 60.0% response (trastuzumab-docetaxel)

    NRG-HN010 (146 people) compares the HER2 drug conjugate T-DM1 with chemotherapy; due July 2028.

    60.0%: response rate.

  5. 5 years

    by late 2031

    Better treatment after surgeryPossible

    SANTAL (342 people) tests chemoradiation vs radiation alone after surgery; due February 2030.

    TROP2 drug conjugatesLong shot

    A trial of sacituzumab tirumotecan targets TROP2, which most adenoid cystic carcinomas carry; due April 2030.

Happened Likely Possible Long shot

The research paths

Rising

HER2-targeted drugs

91.7% response rate
Details and 4 trialsHide
Rising

Hormone therapy

45.2% response rate
Details and 1 trialsHide

Androgen receptor blockers borrowed from prostate cancer.

WatchNCI darolutamide trial.

Active

Radiation and adenoid cystic carcinoma

45% progression-free at 6 months
Details and 4 trialsHide

Borrowed from other cancers

From Prostate cancer

Darolutamide

Phase 2

An androgen receptor blocker approved for prostate cancer.

From Breast and stomach cancer

Trastuzumab and HER2 drug conjugates

Phase 2/3

HER2-targeted drugs first approved for breast cancer.

From Breast and lung cancer

Sacituzumab tirumotecan

Phase 2

A TROP2-directed drug conjugate.

Open to join now

See every recruiting Salivary gland cancer trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Dec 2026
Dec 2026
Dec 2026
Feb 2028
Chemoradiation vs radiation after surgery (SANTAL)Radiation and adenoid cystic carcinoma
Feb 2030
Sacituzumab tirumotecan (TROP2 drug conjugate)Radiation and adenoid cystic carcinoma
Apr 2030

What just happened

HER2 drug conjugate shrinks 91.7% of HER2-high tumors

J Clin Oncol.

Darolutamide plus goserelin shrinks 45.2% of tumors

DISCOVARY, J Clin Oncol.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Salivary gland cancer trials recruiting now →

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.